State Street’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-899,074
| Closed | -$11.8M | – | 4275 |
|
|
2025
Q4 | $11.8M | Buy |
899,074
+8,404
| +0.9% | +$100K | ﹤0.01% | 2559 |
|
|
2025
Q3 | $6.48M | Sell |
890,670
-43,450
| -5% | -$294K | ﹤0.01% | 2876 |
|
|
2025
Q2 | $5.01M | Sell |
934,120
-30,789
| -3% | -$149K | ﹤0.01% | 2942 |
|
|
2025
Q1 | $5.15M | Sell |
964,909
-446,307
| -32% | -$3.12M | ﹤0.01% | 2872 |
|
|
2024
Q4 | $12.6M | Sell |
1,411,216
-145,067
| -9% | -$1.54M | ﹤0.01% | 2486 |
|
|
2024
Q3 | $17.1M | Sell |
1,556,283
-495,436
| -24% | -$5.51M | ﹤0.01% | 2306 |
|
|
2024
Q2 | $18.7M | Sell |
2,051,719
-167,953
| -8% | -$1.64M | ﹤0.01% | 2203 |
|
|
2024
Q1 | $31.2M | Buy |
2,219,672
+1,689,924
| +319% | +$21M | ﹤0.01% | 1964 |
|
|
2023
Q4 | $4.07M | Buy |
529,748
+35,690
| +7% | +$197K | ﹤0.01% | 3038 |
|
|
2023
Q3 | $3.69M | Buy |
494,058
+15,892
| +3% | +$136K | ﹤0.01% | 3076 |
|
|
2023
Q2 | $3.98M | Buy |
478,166
+404,784
| +552% | +$4.67M | ﹤0.01% | 3103 |
|
|
2023
Q1 | $976K | Buy |
73,382
+25,100
| +52% | +$339K | ﹤0.01% | 3542 |
|
|
2022
Q4 | $719K | Buy |
48,282
+19,200
| +66% | +$198K | ﹤0.01% | 3645 |
|
|
2022
Q3 | $263K | Buy |
+29,082
| New | +$195K | ﹤0.01% | 4022 |
|
|
2021
Q3 | – | Sell |
-9,500
| Closed | -$120K | – | 4689 |
|
|
2021
Q2 | $120K | Sell |
9,500
-81,980
| -90% | -$1.06M | ﹤0.01% | 4327 |
|
|
2021
Q1 | $1.59M | Buy |
91,480
+30,509
| +50% | +$551K | ﹤0.01% | 3518 |
|
|
2020
Q4 | $783K | Buy |
60,971
+20,686
| +51% | +$369K | ﹤0.01% | 3596 |
|
|
2020
Q3 | $1.5M | Buy |
40,285
+6,693
| +20% | +$265K | ﹤0.01% | 3308 |
|
|
2020
Q2 | $1.3M | Buy |
+33,592
| New | +$1.2M | ﹤0.01% | 3343 |
|
|
2018
Q4 | – | Sell |
-302
| Closed | -$14K | – | 3766 |
|
|
2018
Q3 | $14K | Hold |
302
| – | – | ﹤0.01% | 3751 |
|
|
2018
Q2 | $17K | Hold |
302
| – | – | ﹤0.01% | 3741 |
|
|
2018
Q1 | $33K | Hold |
302
| – | – | ﹤0.01% | 3687 |
|
|
2017
Q4 | $27K | Hold |
302
| – | – | ﹤0.01% | 3675 |
|
|
2017
Q3 | $38K | Hold |
302
| – | – | ﹤0.01% | 3681 |
|
|
2017
Q2 | $26K | Hold |
302
| – | – | ﹤0.01% | 3643 |
|
|
2017
Q1 | $29K | Buy |
+302
| New | +$41.6K | ﹤0.01% | 3598 |
|
State Street's ATXS Position: Q1 2026 in Review
State Street sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 899,074 shares — an estimated $11.8M sold.
State Street first reported a position in ATXS in Q1 2017 and held it in 26 quarters. The position peaked at $31.2M in Q1 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- State Street reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- State Street sold 899,074 Astria Therapeutics shares in Q1 2026, an estimated $11.8M.
- State Street first reported a position in Astria Therapeutics in Q1 2017 and held it in 26 quarters.
- State Street's Astria Therapeutics position peaked at $31.2M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.